How long can you stay on Wegovy 2.4mg — and what happens next?

The two-year ceiling and what it actually means day to day

A question our prescribers hear most weeks is some version of: "I've only just reached 2.4mg — does the clock reset?" It does not. NICE's appraisal of semaglutide (TA875) recommends treatment for a maximum of two years, within a specialist weight management service that includes multidisciplinary support. That two-year period begins at your first dose of Wegovy, regardless of which strength you are taking. Because the titration schedule moves through 0.25mg, 0.5mg, 1.0mg and 1.7mg before reaching 2.4mg, most people spend four to five months getting there, and if you are wondering how long you typically stay on the 0.5mg dose before moving up, that page explains the usual timeframe in detail. That leaves somewhere between nineteen and twenty months at 2.4mg if everything goes well and the full two years is appropriate.

It is worth being precise about what the recommendation actually says: it is a recommended maximum, not an automatic endpoint. A prescriber may review your treatment earlier, extend beyond two years in specific clinical circumstances if clinical judgement supports it, or decide that stopping sooner is right for you. The NHS England guidance on weight management injections reinforces that these decisions sit with the clinical team overseeing your care, alongside the diet and activity support that is part of any legitimate programme.

The six-month response check: a built-in decision point

Before the two-year window comes to an end, there is an earlier checkpoint worth understanding. NICE's guidance is clear: if you have not achieved at least 5% weight loss after six months at the highest dose you can tolerate (which for most people on the full schedule is 2.4mg), a prescriber should review whether continuing is appropriate. This is not a punishment clause; it reflects the clinical reality that semaglutide does not produce meaningful weight loss in everyone, and continuing treatment indefinitely without measurable benefit carries risks as well as costs.

The six-month count starts from when you reach the maintenance dose, so the timing is individual. Some people respond strongly and the decision at six months is straightforward. Others lose weight more slowly or plateau, and that conversation is more nuanced. How long you spend on each dose of Wegovy before reaching 2.4mg affects when that response review falls within the broader two-year window. Either way, the check is part of the care, not a surprise.

What stopping 2.4mg usually involves, and why it matters to plan ahead

For most people, stopping Wegovy at any dose means weight begins to return unless the lifestyle changes built during treatment are well established. The clinical trials did not study indefinite use, and the two-year NHS recommendation reflects both what the evidence covers and safety considerations over longer periods. None of that means treatment is ineffective; it means the aim is to use the two years to build sustainable habits alongside the medication, with prescriber and dietitian support.

If you are approaching the end of a treatment course and thinking about what comes next, that conversation belongs with your prescriber rather than in an online forum. Some people transition to a lower maintenance dose for a period; others stop cleanly. Whether a further course is ever clinically appropriate is a question the evidence has not fully answered, and responsible prescribers will say so plainly. You can read through commonly asked questions about Wegovy and semaglutide for broader context, but individual decisions need individual review. The cost of private Wegovy treatment is one practical factor people weigh as a course nears its end, and it is worth factoring that in early rather than making a rushed decision.

NHS versus private prescribing: does the pathway change the duration?

On the NHS, access to Wegovy runs through specialist weight management services, and the two-year NICE maximum applies within that system. Private prescribing follows the same clinical guidance, even though the access route is different. A legitimate private prescriber applies the same two-year consideration and the same six-month response check; the medicine and its evidence do not change depending on who is paying for it.

What does differ is how closely your progress is monitored. At nume, every repeat order is reviewed by a GPhC-registered prescriber before it is approved, rather than auto-renewed. That means duration decisions are made actively, not by default. If you are partway through a course and considering a transfer from another provider, starting a free consultation is the point at which our prescribers can review your treatment history and advise on next steps. Missed doses and what to do about them are a related practical question; guidance on missed Wegovy doses covers what the evidence says about gaps and how to handle them. The broader picture of all the Wegovy dose strengths can also help you understand where 2.4mg sits in the full schedule.